Literature DB >> 27372348

Treatment of adult and pediatric high-grade gliomas with Withaferin A: antitumor mechanisms and future perspectives.

Megan M Marlow1, Sumedh S Shah1, Eduardo A Véliz2, Michael E Ivan1, Regina M Graham3.   

Abstract

Resistance mechanisms employed by high-grade gliomas allow them to successfully evade current standard treatment of chemotherapy and radiation treatment. Withaferin A (WA), utilized in Ayurvedic medicine for centuries, is attracting attention for its antitumor capabilities. Here we review pertinent literature on WA as a high-grade glioma treatment, and discuss the cancerous mechanisms it affects. WA is relatively nontoxic and has shown potential in crossing the blood-brain barrier. WA prevents p53 alterations and inactivates overexpressed MDM2 through ARF and ROS production. Furthermore, WA upregulates Bax, inducing mitochondrial death cascades, inhibits mutated Akt, mTOR, and NF-κB pathways, and inhibits angiogenesis in tumors. Therapy with WA for high-grade gliomas is supported through the literature. Further investigation is warranted and encouraged to fully unearth its abilities against malignant gliomas.

Entities:  

Keywords:  Astrocytoma; Brain cancer; Chemotherapy; Experimental therapy; Glioblastoma; High-grade glioma; Mechanisms of action; Withaferin A

Mesh:

Substances:

Year:  2016        PMID: 27372348     DOI: 10.1007/s11418-016-1020-2

Source DB:  PubMed          Journal:  J Nat Med        ISSN: 1340-3443            Impact factor:   2.343


  74 in total

1.  Withaferin A, a cytotoxic steroid from Vassobia breviflora, induces apoptosis in human head and neck squamous cell carcinoma.

Authors:  Abbas K Samadi; Xiaoqin Tong; Ridhwi Mukerji; Huaping Zhang; Barbara N Timmermann; Mark S Cohen
Journal:  J Nat Prod       Date:  2010-09-24       Impact factor: 4.050

2.  PTEN status switches cell fate between premature senescence and apoptosis in glioma exposed to ionizing radiation.

Authors:  J-J Lee; B C Kim; M-J Park; Y-S Lee; Y-N Kim; B L Lee; J-S Lee
Journal:  Cell Death Differ       Date:  2010-11-12       Impact factor: 15.828

3.  Acylation: a proposed mechanism of action for various oncolytic agents based on model chemical systems.

Authors:  J W Moncrief; K S Heller
Journal:  Cancer Res       Date:  1967-08       Impact factor: 12.701

Review 4.  Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.

Authors:  D Hanahan; J Folkman
Journal:  Cell       Date:  1996-08-09       Impact factor: 41.582

5.  Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation.

Authors:  Patrick T Grogan; Jann N Sarkaria; Barbara N Timmermann; Mark S Cohen
Journal:  Invest New Drugs       Date:  2014-04-10       Impact factor: 3.850

6.  Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies.

Authors:  Michael Frumovitz; Anil K Sood
Journal:  Gynecol Oncol       Date:  2007-03       Impact factor: 5.482

Review 7.  Aberrant rel/nfkb genes and activity in human cancer.

Authors:  B Rayet; C Gélinas
Journal:  Oncogene       Date:  1999-11-22       Impact factor: 9.867

8.  Ayurvedic medicine constituent withaferin a causes G2 and M phase cell cycle arrest in human breast cancer cells.

Authors:  Silvia D Stan; Yan Zeng; Shivendra V Singh
Journal:  Nutr Cancer       Date:  2008       Impact factor: 2.900

9.  Ras inhibition by FTS attenuates brain tumor growth in mice by direct antitumor activity and enhanced reactivity of cytotoxic lymphocytes.

Authors:  Elizabeta Aizman; Adi Mor; Ayelet Levy; Jacob George; Yoel Kloog
Journal:  Oncotarget       Date:  2012-02

10.  JNK-NQO1 axis drives TAp73-mediated tumor suppression upon oxidative and proteasomal stress.

Authors:  A Kostecka; A Sznarkowska; K Meller; P Acedo; Y Shi; H A Mohammad Sakil; A Kawiak; M Lion; A Królicka; M Wilhelm; A Inga; J Zawacka-Pankau
Journal:  Cell Death Dis       Date:  2014-10-23       Impact factor: 8.469

View more
  3 in total

1.  Chalcones as Anti-Glioblastoma Stem Cell Agent Alone or as Nanoparticle Formulation Using Carbon Dots as Nanocarrier.

Authors:  Eduardo A Veliz; Anastasiia Kaplina; Sajini D Hettiarachchi; Athina L Yoham; Carolina Matta; Sabrin Safar; Meghana Sankaran; Esther L Abadi; Emel Kirbas Cilingir; Frederic A Vallejo; Winston M Walters; Steven Vanni; Roger M Leblanc; Regina M Graham
Journal:  Pharmaceutics       Date:  2022-07-14       Impact factor: 6.525

2.  Implications of Withaferin A in neurological disorders.

Authors:  Natasha Ram; Stephanie L Peak; Andres R Perez; Umesh K Jinwal
Journal:  Neural Regen Res       Date:  2021-02       Impact factor: 5.135

3.  Integrative Analysis of a Novel Eleven-Small Nucleolar RNA Prognostic Signature in Patients With Lower Grade Glioma.

Authors:  Teng Deng; Yizhen Gong; Xiwen Liao; Xiangkun Wang; Xin Zhou; Guangzhi Zhu; Ligen Mo
Journal:  Front Oncol       Date:  2021-06-07       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.